Press Releases for AGIX

Press Releases
AtheroGenics Receives Delisting Notice From NASDAQ Global Market Due to Chapter 11 Filing
Zacks Analyst Blog Highlights: Wipro, Ltd., Skechers USA, Inc., Coca- Cola Hellenic Bottling Co., Scientific Games Corp. And AtheroGenics, Inc.
AtheroGenics Files for Chapter 11 Bankruptcy
Zacks Analyst Blog Highlights: Toyota Motor Corp., Jamba, Inc., AtheroGenics, Inc., Vodafone Group Plc. And Xilinx, Inc.
AtheroGenics Restructures Board of Directors
AtheroGenics Seeks to Realign Capital Structure
AtheroGenics Reports Second Quarter 2008 Financial Results
BeaconEquity.com Issues Technical Trade Alerts on Market Movers: AGIX, APKT, BIOS, NOVA, CNXT, CHRD
AtheroGenics Reports Positive Results From ANDES Phase 3 Clinical Trial of AGI-1067 in Type 2 Diabetes
AtheroGenics to Report Second Quarter 2008 Financial Results on August 5, 2008
AtheroGenics Receives Notice of Non-Compliance With Listing Requirement for the NASDAQ Global Market
BeaconEquity.com Issues TraderNotes on Stocks: TPIM, NSM, BRLC, AGIX, AROX, TLEO, HLYS, ABAT
AtheroGenics Reports Clinical Data on Novel Anti-Inflammatory Anti-Oxidant Agent, AGI-1067, at American Diabetes Association Annual Meeting
AtheroGenics Announces Five Abstracts Accepted for the American Diabetes Association's 68th Annual Scientific Sessions
AtheroGenics' ARISE Trial Results Published in The Lancet - May 26 2008 10:31PM
/ CORRECTION - AtheroGenics to Present at the 2008 Morgan Stanley Global Healthcare Unplugged Conference on May 2, 2008
AtheroGenics to Present at the 2008 Morgan Stanley Global Healthcare Unplugged Conference on May 2, 2008
AtheroGenics Reports First Quarter 2008 Financial Results
AtheroGenics to Report First Quarter 2008 Financial Results on April 24, 2008
BellwetherReport.com Initiates Analyst Coverage on AGIX, FRNT, AAI and BBI
AtheroGenics Announces Encouraging Interim Results From Phase 3 Clinical Trial of AGI-1067 in Type 2 Diabetes